WuXi AppTec
United States
About WuXi AppTec
126 articles about WuXi AppTec
-
WuXi STA Announces to Build a New R&D Center in Shanghai
4/27/2018
STA Pharmaceutical Co., Ltd. announces that it has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.
-
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
-
WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services
4/19/2018
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.
-
With the cutting of a ribbon more than 200 new jobs are expected to be created as China-based WuXi AppTec officially opened its expanded Laboratory Testing Division (LTD) facility in New Jersey.
-
WuXi AppTec Expands Site in the United States for Drug Development Testing Services
4/19/2018
WuXi AppTec announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.
-
Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND
4/16/2018
PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer
-
Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies
3/21/2018
“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla.
-
JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.
-
WuXi AppTec Launches Advanced Library Compound Initiative on LabNetwork.com
2/6/2018
The new online platform allows users to input search parameters by utilizing one of two molecular structure drawing tools provided on the site, or by uploading search data files.
-
WuXi AppTec Group and Mayo Clinic Form Joint Venture to Deliver Clinical Diagnostic Services
1/10/2018
WuXi AppTec and Mayo Clinic announced today a joint venture to co-develop and deliver clinical diagnostic services in China.
-
The incubator will be located at Merck Serono's current facilities in Yavne, a town in central Israel.
-
WuXi AppTec Selected by IQVIA Stem Cell Center to Serve as GMP Manufacturer of Advanced Therapies
11/17/2017
In collaboration with its partners, the Stem Cell Center aims to accelerate the preclinical/clinical development, and commercialization of stem cell, cellular and gene-modified therapies via end-to-end solutions and targeted services to advance assets from candidate identification through market authorization and improve the probability of clinical and commercial success.
-
Week in Review: WuXi AppTec Acquires US-Global Clinical CRO
10/23/2017
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
-
STA Pharmaceutical to Open New Transition Metal Catalysis Center in Changzhou, China
10/20/2017
STA Pharmaceutical, a WuXi AppTec company, has announced plans to launch a new transition metal catalysis center at their integrated API process R&D and manufacturing site in Changzhou China.
-
WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.
-
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements In Decades On Cancer Treatments
8/10/2017
-
WuXi AppTec Merges Formulation/Finishing Services Into API Manufacturing Division
8/1/2017
-
WuXi AppTec's Pharmaceutical Development Services Division Merges With STA Pharmaceutical
7/31/2017
-
WuXi AppTec Participates In $5.9 Million Series A For Rodeo Therapeutics
7/26/2017
-
WuXi AppTec Completes Acquisition Of HD Biosciences Co., Ltd
5/15/2017